Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06565442 · ClinicalTrials.gov registry record

Feasibility of Using NeuraSignal Transcranial Doppler Robot

A clinical trial, sponsored by University of Alabama at Birmingham.

Not yet
Registry status
20
Enrollment target

NCT06565442: Clinical Trial study, sponsored by University of Alabama at Birmingham.

NCT06565442 is a clinical trial that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06565442 has not yet begun recruiting, sponsored by University of Alabama at Birmingham.

NOT YET RECRUITING
Registry status
20 participants
Enrollment target

Study Summary

The purpose of this study is to determine the feasibility of using the NeuraSignal transcranial doppler robot in a neuro ICU setting to measure cerebral blood flow correlated with arterial blood pressure to generate individualized cerebral autoregulatory curves

Primary Outcome

Cerebral autoregulatory curve generation using the NeuraSignal transcranial doppler robot correlated with arterial blood pressure measurements in neuro ICU patients admitted for blood pressure management after spinal surgery

Interventions

  • DEVICE NeuraSignal transcranial doppler robot

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2026-06-15
Est. Completion 2027-12-15
University of Alabama at Birmingham

1,160 total trials

What is known before NCT06565442 opens enrollment

NCT06565442 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which NeuraSignal transcranial doppler robot is the first listed.

NCT06565442 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06565442 about?

NCT06565442 is a clinical study titled "Feasibility of Using NeuraSignal Transcranial Doppler Robot". The purpose of this study is to determine the feasibility of using the NeuraSignal transcranial doppler robot in a neuro ICU setting to measure cerebral blood flow correlated with arterial blood pressure to generate individualized cerebral autoregulatory curves

What is the current status of trial NCT06565442?

This trial is currently not yet recruiting. The enrollment target is 20 participants. The study started on 2026-06-15. Estimated completion is 2027-12-15.

What interventions are being tested in trial NCT06565442?

The interventions under investigation include: NeuraSignal transcranial doppler robot (DEVICE).

Who is sponsoring clinical trial NCT06565442?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06565442, the US trial registry maintained by the National Library of Medicine. NCT06565442 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.